title: [Molecular features of metanephric adenoma and their values in differential diagnosis].
abstract: Objective:To study the molecular features of metanephric adenoma (MA) and discuss their values in differential diagnosis.Methods:BRAF V600E immunohistochemistry (IHC) using the mutation-specific VE1 monoclonal antibody and Sanger sequencing of BRAF mutations were performed on 21 MAs, 16 epithelial-predominant Wilms tumors (e-WT) and 20 the solid variant of papillary renal cell carcinomas (s-PRCC) respectively. p16 protein was detected by IHC also. Fluorescence in situ hybridization (FISH) analyses using centromeric probes for chromosome 7 and 17 were performed on the three renal tumors in parallel.Results:Fourteen (14/21, 66.7%) of 21 MA cases demonstrated diffuse, moderate to strong cytoplasmic BRAF V600E IHC staining and the BRAF V600E protein expression was detected in 2 (2/16) of 16 e-WT cases for the first time, whereas all s-PRCCs were negative (P<0.05). All cases (including 14 MAs and 2 e-WTs) with diffuse, moderate to strong cytoplasmic BRAF V600E IHC staining were confirmed to harbor BRAF V600E missense mutations using Sanger sequencing, and no BRAF mutations were detected in cases with negative BRAF V600E protein expression. One case (1/21, 4.8%) showed trisomy of chromosome 7 alone, and another one (1/21, 4.8%) showed trisomy of chromosome 17 alone in 21 MAs. Two cases (2/16) of 16 e-WTs showed trisomy of chromosome 17 alone. In 20 s-PRCCs, trisomy of chromosomes 7 alone was reported in 2 cases (2/20), trisomy of chromosome 17 alone in 3 cases (3/20) and trisomy of chromosome 7 and 17 in 14 cases (14/20). The total positive rates of trisomy of chromosome 7 and/or 17 in MAs, e-WTs and s-PRCCs were 9.6% (2/21), 2/16 and 95.0% (19/20). p16 protein was positive in 81.0% (17/21) MAs, whereas the positive rates in e-WTs and s-PRCCs were 2/16 and 5.0% (1/20).Conclusions:Most MAs harbor BRAF V600E mutations, and MAs lack the gains of chromosome 7 and 17 that are characteristic of papillary renal cell carcinoma. These molecular features can be used to distinguish MA from its mimics. BRAF V600E IHC using the mutation-specific VE1 monoclonal antibody provides an effective method in BRAF V600E mutations detection of renal tumors. p16 is overexpressed in MA, and the finding suggests that the low proliferative rate of the tumor might be attributed to BRAF V600E-induced senescence mediated by p16.
authors.affiliation: Department of Pathology, Medicine School of Nanjing University/Nanjing Jinling Hospital, Nanjing 210002, China.
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: S S
authors.initials: SS
authors.lastname: Shi
authors.forename: W R
authors.initials: WR
authors.lastname: Yang
authors.forename: S B
authors.initials: SB
authors.lastname: Ye
authors.forename: R
authors.initials: R
authors.lastname: Li
authors.forename: H H
authors.initials: HH
authors.lastname: Ma
authors.forename: R S
authors.initials: RS
authors.lastname: Zhang
authors.forename: Z F
authors.initials: ZF
authors.lastname: Lu
authors.forename: X J
authors.initials: XJ
authors.lastname: Zhou
authors.forename: Q
authors.initials: Q
authors.lastname: Rao
mesh_terms: D000236:Adenoma / Q000235:genetics*; D000911:Antibodies, Monoclonal; D002292:Carcinoma, Renal Cell / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17; D002897:Chromosomes, Human, Pair 7; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis; D004252:DNA Mutational Analysis; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D007680:Kidney Neoplasms / Q000235:genetics*; D009154:Mutation; D020125:Mutation, Missense; D048493:Proto-Oncogene Proteins B-raf / Q000032:analysis / Q000235:genetics*; D014314:Trisomy; D009396:Wilms Tumor / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; D019941:Cyclin-Dependent Kinase Inhibitor p16; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf